Defining the Role of Adjuvant Chemotherapy After Lobectomy for Typical Bronchopulmonary Carcinoid Tumors

Nussbaum, Daniel P.; Speicher, Paul J.; Gulack, Brian C.; Hartwig, Matthew G.; Onaitis, Mark W.; D’Amico, Thomas A.

doi:10.1016/j.athoracsur.2014.08.030

Cited by 45 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially for the resectable low-grade TCs, adjuvant chemotherapy seems to confer no survival benefit, even when lymph nodes are involved. According to a recent large study of Nussbaum et al, no survival advantage was demonstrated at 5 years when adjuvant chemotherapy was administered after lobectomy for TC (9). Despite the limitations of this study, these results are in line with current recommendations, suggesting only observation after surgery (10).…”

Section: Adjuvant Therapysupporting

confidence: 86%

Advances on systemic treatment for lung neuroendocrine neoplasms

et al. 2018

View full text Add to dashboard Cite

Lung well-to-moderately differentiated neuroendocrine tumors (also known as carcinoids) and large cell neuroendocrine lung carcinoma (poorly differentiated neuroendocrine tumor) are rare neuroendocrine neoplasms, which account for less than 4% of all lung neoplasms. Due to their low incidence, their systemic treatment is greatly influenced by therapeutic evidence derived from the more frequent gastroenteropancreatic neuroendocrine neoplasms and/or small cell lung carcinoma leading to significant bias. Currently, employed systemic therapies for lung carcinoids, aiming at controlling tumor growth include long acting somatostatin analogues (SSAs), peptide receptor radionuclide therapy, chemotherapy and molecular-targeted therapy. In this review, each of those treatments is presented based upon available clinical evidence from retrospective and prospective studies particularly focused on the role of everolimus in the advanced setting and on ongoing clinical trials reflecting our expectations in the near future. In addition, we critically analyse currently employed treatment of large cell neuroendocrine carcinoma where the appropriate chemotherapeutic regimen is still a matter of debate.

show abstract

Section: Adjuvant Therapysupporting

confidence: 86%

Advances on systemic treatment for lung neuroendocrine neoplasms

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Systemic therapy is generally recommended for metastatic disease; however, the results with chemotherapy have been largely disappointing. 3 Given that chemotherapy is not routinely used or recommended in the adjuvant setting as it does not improve survival, 13 we can infer from our results that most patients with metastatic disease are treated with chemotherapy, despite the poor reported response rates with this treatment. To the best of our knowledge, this is the first time that the use of chemotherapy has been reported on a large scale for patient with PC tumours.…”

Section: Discussionmentioning

confidence: 86%

Patient characteristics, treatment and survival in pulmonary carcinoid tumours: an analysis from the UK National Lung Cancer Audit

et al. 2016

View full text Add to dashboard Cite

ObjectivesPulmonary carcinoid (PC) is a rare tumour with good prognosis following surgical resection. However, little is known regarding patient characteristics and use of other treatments modalities. Our objective was to review patient characteristics, treatment and survival for patients with PC and contrast these results with other forms of non-small cell lung cancer (NSCLC).SettingAudit data from UK National Lung Cancer Audit (NLCA) 2008–2013.Participants184 906 lung cancer cases were submitted to the NLCA.Outcome measuresPrimary outcome—survival rates between PC and NSCLC. Secondary outcome—differences in performance status, lung function and treatment modality between PC and NSCLC.ResultsPC histology was recorded in 1341 (0.73%) patients and non-carcinoid NSCLC histology in 162 959 (87.4%) cases. 91% of patients with PC had good performance status (Eastern Cooperative Oncology Group (ECOG) 0–1), compared with only 53% of NSCLC. 66% of PC had localised disease. Of all PC cases, 77% were treated with surgery, 6.2% received chemotherapy and 3.6% received radiotherapy, with the remainder treated with best supportive care. Overall 1-year and 3-year survival rates for PC were 92% and 84.7%, respectively. In contrast, 1-year and 3-year survival rates for NSCLC were 36.2% and 15.6%, However, 3-year survival for PC markedly decreased with worsening performance status and advanced disease to 23.8% for performance status ECOG 3–4 and 33.6% for stage IV disease.ConclusionsIn contrast to other forms of NSCLC, the majority of patients with PC present with good performance status, preserved lung function and early stage disease amenable to surgical resection. However, 1 in 5 patients with PC has metastatic disease which is associated with poor prognosis, as is poor performance status at presentation. We believe these data will help clinicians provide accurate prognostic predictions stratified according to patient characteristics at presentation, as well as guide future clinical trials.

show abstract

“…Daniel et al. considered that adjuvant chemotherapy did not improve the survival of patients who underwent lobectomy for TCs with lymph node metastases. In contrast, Caplin et al.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population‐based study

Huang¹,

Yang²,

Lu³

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

Previous studies have identified potential risk factors for pulmonary carcinoid tumors and evaluated the effect of various treatments; however, the results were not entirely consistent. We conducted a population‐based study to further explore relevant prognostic issues. We extracted cases with pulmonary carcinoid tumors from the Surveillance Epidemiology and End Results database. Cox proportional hazard regression was utilized to identify potential significant risk factors, which helped establish a nomogram for predicting long‐term survival. Survival analysis and a competing risk study were conducted to evaluate the value of different surgical approaches. There were 7057 cases included in the study. Univariate and multivariate analyses showed that age, sex, tumor size, stage, histology, surgical type, chemotherapy, and radiation therapy were all significant prognostic factors. A nomogram with good accuracy for predicting 10‐year survival was formulated. Furthermore, patients who had undergone surgery had a significantly better survival than those who did not undergo surgery. There was no significant prognostic difference between lobectomy and sublobectomy stratified by tumor stage; however, lobectomy was associated with a significantly better survival in atypical tumors, especially those with regional disease. Our research identified possible risk factors in a large cohort and constructed a nomogram to visually predict 10‐year survival of pulmonary carcinoid tumors. We showed that lobectomy and sublobectomy should be considered as the mainstay of treatment, especially lobectomies for atypical tumor.

show abstract

Defining the Role of Adjuvant Chemotherapy After Lobectomy for Typical Bronchopulmonary Carcinoid Tumors

Cited by 45 publications

References 10 publications

Advances on systemic treatment for lung neuroendocrine neoplasms

Advances on systemic treatment for lung neuroendocrine neoplasms

Patient characteristics, treatment and survival in pulmonary carcinoid tumours: an analysis from the UK National Lung Cancer Audit

Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population‐based study

Contact Info

Product

Resources

About